OCT 29, 2014 03:00 PM PDT

Transforming the future of oncology with genomics

12 40 1421

  • Senior Market Manager, Oncology , Illumina
      Dr. Jennifer Stone joined Illumina in 2009 and is responsible for market development for the oncology business.  Before joining Illumina, Dr. Stone held a post-doctoral fellowship position at the Broad Institute of Harvard and MIT and Massachusetts General Hospital, with a focus on complex disease genetics and large-scale study design and analysis.  She earned a bachelors in chemistry from The College of William and Mary in Virginia, and an PhD in Human Genetics from the University of California, Los Angeles..


    Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection and molecular monitoring.

    Join us for a review of Illuminas areas of focus for development of sample-to-data solutions, including whole-genome and targeted sequencing approaches. Learn how these solutions are now delivering relevant oncological information into the hands of translational and clinical researchers. Hear about groundbreaking developments in cancer genomics from around the world, including:

    • Whole-genome and targeted sequencing of DNA
    • Germ line investigations
    • Deep sequencing of circulating nucleic acids as non-invasive bio markers


    Show Resources
    Loading Comments...